Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group (Q73117996)
Jump to navigation
Jump to search
scientific article published on 01 October 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group |
scientific article published on 01 October 2000 |
Statements
Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group (English)
M Poeze
A H Froon
G Ramsay
W A Buurman
1 October 2000